JPMorgan Upgrades CAMP4 Therapeutics Corp (CAMP) to Overweight

June 16, 2026 12:37 AM

JPMorgan analyst Anupam Rama upgraded CAMP4 Therapeutics Corp (NASDAQ: CAMP) from Neutral to Overweight with a price target of $9.00 ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found